Get the Stockscreener App
8.6241
1.78%
-0.1559
After Hours:
8.62
-0.0041
-0.05%
Addex Therapeutics Ltd Adr stock is traded at $8.6241, with a volume of 24,783.
It is down -1.78% in the last 24 hours and down -21.67% over the past month.
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
See More
Previous Close:
$8.78
Open:
$8.83
24h Volume:
24,783
Relative Volume:
0.08
Market Cap:
$9.38M
Revenue:
$2.23M
Net Income/Loss:
$-12.33M
P/E Ratio:
-6.4615
EPS:
-1.3347
Net Cash Flow:
$-11.75M
1W Performance:
+16.86%
1M Performance:
-21.67%
6M Performance:
+7.67%
1Y Performance:
+50.51%
1-Day Range:
$8.375
$8.94
1-Week Range:
$7.01
$9.06
52-Week Range:
$5.00
$27.90
Addex Therapeutics Ltd Adr Stock (ADXN) Company Profile
Name
Addex Therapeutics Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare ADXN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADXN
Addex Therapeutics Ltd Adr
|
8.6241 | 9.38M | 2.23M | -12.33M | -11.75M | -1.3347 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Addex Therapeutics Ltd Adr Stock (ADXN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
Addex Therapeutics Ltd Adr Stock (ADXN) Latest News
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? - Yahoo Finance
Addex Stock Soars on Crucial Update From Indivior Research Deal - MSN
Golden Heaven Group secures investment of $25.2M - MSN
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year? - Yahoo Finance
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024 - GlobeNewswire Inc.
Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock - MSN
Are Medical Stocks Lagging Boston Scientific (BSX) This Year? - Yahoo Finance
What Makes Addex Therapeutics (ADXN) a New Buy Stock - Yahoo Finance
Earnings call: Addex Therapeutics reports half-year financials and R&D updates By Investing.com - Investing.com South Africa
Earnings call: Addex Therapeutics reports half-year financials and R&D updates - Investing.com
ADMA Biologics stock soars to all-time high of $19.36 - Investing.com
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest? - Zacks Investment Research
ADMA Biologics (NASDAQ:ADMA) Reaches New 52-Week High at $19.42 - MarketBeat
ADXN Stock on the Rise: A Promising Investment - The InvestChronicle
There Are Mixed Signals on the Chart for Addex Therapeutics Ltd ADR (ADXN) - US Post News
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder - Yahoo Finance
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is Alcon (ALC) Outperforming Other Medical Stocks This Year? - Yahoo Canada Finance
Addex’s Partner Discontinues ADX71149 development in Epilepsy - GlobeNewswire Inc.
Addex Therapeutics presents results from GABAB PAM cough program - TipRanks
Addex Presents Positive Results from GABAB PAM Cough - GlobeNewswire Inc.
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS) - GlobeNewswire Inc.
Addex to Participate at the Benchmark Company Healthcare House Call Conference - The Globe and Mail
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Canada Shine On
Earnings call: Addex Therapeutics reports on Q1 2024 with mixed results - Investing.com India
Earnings call: Addex Therapeutics reports on Q1 2024 with mixed results By Investing.com - Investing.com
Genocea (GNCA) Begins Phase I/IIa Study for Solid Tumor Drug - Yahoo Movies UK
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Movies UK
Why Philips Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket - Benzinga
Addex Therapeutics Receives Nasdaq Approval for ADS Ratio Change By Investing.com - Investing.com India
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo New Zealand News
Addex Therapeutics ADR (NASDAQ: ADXN) Has Moved an M4 PAMS Program to Optimization - BP Journal
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer I - Benzinga
ASLAN Pharma (NASDAQ:ASLN) Stock Quotes, Forecast and News Summary - Benzinga
Addex Therapeutics (ADXN) Stock Price, News & Analysis - MarketBeat
ADXN Stock Price and Chart — SIX:ADXN - TradingView
Addex and the Charcot-Marie-Tooth Association enter collaboration to advance ADX71441 in Charcot-Marie-Tooth 1A ... - Yahoo Eurosport UK
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Addex Therapeutics Ltd Adr Stock (ADXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):